Dec 6 (Reuters) - Novartis AG:
* INTELLIA THERAPEUTICS AND NOVARTIS EXPAND CELL THERAPY COLLABORATION TO PURSUE CRISPR/CAS9-BASED GENOME EDITING IN ADDITIONAL STEM CELL POPULATION
* INTELLIA'S RIGHT TO USE PROPRIETARY LIPID NANOPARTICLE TECHNOLOGY EXTENDED TO ALL SETTINGS
* INTELLIA WILL RECEIVE A ONE-TIME $10 MILLION PAYMENT Further company coverage: (Reporting by Riham Alkousaa)
